2LYER R, WIKINSON N, DEMMY T, et al. Controversies in the muhinmdallty management of locally advanced esophagealcancer: evidence-based review d surgery alone and combined- modaIity thempy[ J ]. Ann Surg Onto1, 2004, 11 (7) : 665 - 673.
4ZE FEN XIAO, ZONG YI YANG, JUN LIANG, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thonac Surg, 2003, 75:331 - 336.
3Saglam EK, Kilciksiz S, Ozseker N, et al. Treatment outcome and prognostic factors in non-metastatic esophageal carcinoma [J]. Saadi Med J,2007,28(7) :1086 - 1090.
4Rice TW, Adelstein DJ, Chidel MA, et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma[ J ]. Thorac Cardiovasc Surg, 2003, 126 (5) :1590 - 1596.
5Saito T, Shigernitsu Y, Kinoshita T, et al. Cisplatin, vindestine, pepleom and concurrent radiation therapy following esophagectomy with lymph adenectomy for patients with an esophageal carcinoma[J]. Oncol,1993, 50(4) :293 -297.
6Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I : comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45: 747-755.
7Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol. IX. IARC scientific: publications No. 160[M], Lyon: IARC, 2007.
8Parkin DM, Chen VM, Ferlay J, et al. Comparability and quality control in cancer registration. IARC technical report No.19[M]. Lyon: IARC, 1994.
9Felay J, Bnrkhard C, Whelan S, et al. Check and conversion programs for cancerregistries. IARC Technical Report No. 42[M]. Lyon: IARC, 2005.
10Felay J. The IARCcrgTools program [EB/OL]. http://www.iacr.com.fr/iarccrgtools.htm, 2006.
